Karyopharm Therapeutics
KPTI
79 hedge funds and large institutions have $225M invested in Karyopharm Therapeutics in 2016 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 7 closing their positions.
310% more call options, than puts
Call options by funds: $762K | Put options by funds: $186K
67% more capital invested
Capital invested by funds: $135M → $225M (+$90.4M)
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
53% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 19
5% more funds holding
Funds holding: 75 → 79 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$22.2M |
| 2 |
Millennium Management
New York
|
+$1.26M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$881K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$621K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$522K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NLVP
New Leaf Venture Partners
New York
|
-$1.5M |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$429K |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$335K |
| 4 |
SIP
Stoneridge Investment Partners
Radnor,
Pennsylvania
|
-$133K |
| 5 |
Bank of New York Mellon
New York
|
-$110K |
KPTI Hedge Fund Activity: Q3 2016 in Review
79 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2016, worth a combined $225M — up 67% from $135M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new KPTI positions and 7 closed out — a net gain of 4 holders — while 29 added to existing stakes and 19 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $22.2M. The largest seller was New Leaf Venture Partners, exiting entirely with an estimated $1.5M sold.
- 79 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2016, up from 75 in Q2 2016.
- Funds reported $225M of Karyopharm Therapeutics stock for Q3 2016, up 67% quarter-over-quarter.
- 11 funds opened new Karyopharm Therapeutics positions in Q3 2016 and 7 closed out, a net change of +4 holders.
- The largest Karyopharm Therapeutics buyer in Q3 2016 was Wellington Management Group, an estimated $22.2M added.
- The largest Karyopharm Therapeutics seller in Q3 2016 was New Leaf Venture Partners, an estimated $1.5M sold.
Based on aggregated 13F filings for Q3 2016.